(Received for publication November 25, 1985) We have recently reported the in vivo augmentation of resistance to experimental Candida albicans injection by amphotericin B in mice and have shown that this event is concurrent with the appearance in the spleen of a highly candidacidal cell population reactive in vitro against 51Cr-labeled yeast cells. In the present study we characterize these in vitro fungicidal effectors as macrophages and describe the conditions of amphotericin B treatment most suitable for inducing candidacidal activity. We also report that macrophages from intact mice can be activated in vitro to become cytotoxic against Candida. The possible mechanisms through which the amphotericin B activated macrophages exert their increased anti-Candida activity are also investigated.
We have previously shown that amphotericin B (AmB) can, under selected experimental conditions, protect mice against systemic challenge with Candida albicans by means of a mechanism largely independent of its chemotherapeutic antifungal activity1). Because of the well known "adjuvant-like" properties of AmB2'3), we started to examine its effects on isolated components of the host defense system, particularly those with candidacidal activity4,5). In the present paper, we report on the activation of splenic macrophages by in vivo or in vitro exposure to AmB, and define the experimental conditions suitable for achieving optimal anti-Candida immunoadjuvant effects. Studies are also described aimed at clarifying the cellular mechanisms through which AmB confers strong anti-Candida activity on macrophages. This effect apparently involves a more rapid ingestion of the yeast combined with greater phagocytic ability of individual macrophages; on incubation of these effectors with live Candida, marked inhibition of hyphae formation is observed. Materials and Methods
Mice
Hybrid (BALB/c CrxDBA/2) F1 (CD2F1: H-2d/H-2d) mice were obtained from Charles River Breeding Laboratories, Calco, Milan, Italy. Chemicals AmB (Fungizone) kindly supplied by E. R. Squibb & Sons, Inc., Princeton, N. J., was provided in vials containing 50 mg of AmB and 41 mg of sodium deoxycholate with 25.2 mg of sodium phosphate as a buffer. The drug was dissolved in sterile, non-pyrogenic 5 % glucose in H2O and injected into the mice intraperitoneally (ip) in a volume of 0.1 ml/10 g of body weight. Under these conditions a solution of 1 mg of AmB per ml gave the routinely used dose of 10 mg of AmB per kg.
C. albicans The C. albicans strain (laboratory identification name, CA-6) used throughout this study was isolated from a clinical specimen and identified by MARCONI et al.6) according to the taxonomic criteria of VAN UDEN and BUCKELY7). The yeast was grown at 28°C under slight agitation in low-glucose Winge medium composed of glucose 0.2 % (w/v) and yeast extract (BBL, Microbiology Systems, Cockeysville, Md.) 0.3% (w/v) until a stationary phase of growth was reached (about 24 hours). Under these conditions, the culture gave a yield of approximately 2.8 x 108 cells per ml, and the organism grew as an essentially pure yeast-phase population. After the 24-hour culture, cells were harvested by low-speed centrifugation (1,000 x g), washed twice in saline, and diluted to the desired density. In the in vivo studies, C. albicans was injected intravenously via the tail vein in a volume of 0.5 ml per mouse.
Cell Fractionation Procedures
(i) Plastic Adherence: Forty million effector cells suspended in a volume of 10 ml of complete RPMI 1640 were incubated for 3 hours at 37°C in a 5 % CO2 atmosphere in 93-mm petri dishes (Nunc, Roskilde, Denmark). At the end of the incubation, the dishes were extensively washed with RPMI 1640 medium to remove the nonadherent cells. The adherent cells were recovered by scraping with a rubber policeman, washed, and resuspended (viability, 80 to 90%) in complete RPMI 1640.
(ii) Nylon Column: Effector cells were passed over a nylon fiber column as previously described8). Briefly, the sterile nylon columns were rinsed with 20 ml of RPMI supplemented with 5 % fetal calf serum. The columns were drained of excess medium and then replaced in sterile syringe covers and put in a CO, incubator at 37°C at least 1 hour before loading of cells. Then 108 cells in a volume of 2 ml were added to the column and washed into the nylon wool with 0.5 to I ml of warm (37°C) medium. The columns were replaced in the sterile syringe covers and left for 45 minutes at 37°C. The columns were then washed slowly with warm (37°C) medium, the first 25 ml of effluent was collected in 50-ml conical tubes, and the cells were pelletted at 290 x g for 10 minutes at 4°C. Cell recovery was about 30%.
(iii) Carbonyl-iron Powder and Magnet: Removal of phagocytic cells from the effector cell population was performed as previously described9). Briefly, 25 ml of spleen cell suspension (10° cells per ml) was incubated with 25 mg of carbonyl-iron powder (G.A.F. Corp., New York, N.Y.) in a 50-ml conical tube (Falcon Plastics, Oxnard, CA) for 60 minutes at 37°C. To remove the cells that ingested iron particles, the tube was placed on the top of a magnet, and the supernatant was removed. This last step was repeated six to eight times. The cells were then washed and used as effectors in the microcytotoxicity assays.
(iv) Treatment with Anti-theta(Anti-Thy 1.2) Serum Plus Complement: Monoclonal antibodies to Thy 1.2 were purchased from New England Nuclear Corp., Boston, MA (lot LK 114). Thirty million spleen cells were preincubated with anti-Thy 1.2 antiserum diluted 1 : 100 in complete RPMI 1640 medium for 30 minutes at room temperature, washed once in complete RPMI 1640, suspended in a 1 : 4 dilution of low-toxicity-m rabbit complement (Cedarlane Laboratories, Hornby, Ontario, Canada), and incubated for 45 minutes at 37°C. The surviving cells were then washed twice and counted. In all experiments a complement control was performed in which the first incubation was in medium alone and the second incubation was with complement. Cell recovery was between 50 and 60%.
(v) Treatment with Anti-Asialo GM1 Antiserum Plus Complement: The antiserum, previously shown to react selectively with mouse NK cells10) was obtained from Wako Chemicals GmbH, Diisseldorf, West Germany. Spleen cells were treated with a 1/200 dilution of antiserum in RPMI 1640 medium for 30 minutes at room temperature, washed twice, suspended in a 1/4 dilution of low-toxicity-m rabbit complement, and incubated for 1 hour at 37°C. The surviving cells were then washed twice, counted, and tested for residual activity in the microcytotoxicity assays.
Preparation of Effector Cells
For the in vitro assays, effector cells from 5 to 10 animals were pooled. Spleen cell suspensions were obtained by standard methods.
51Cr -release Assay against C. albicans
The candidacidal activity of various effector cell populations was assessed by means of a previously described method11). Briefly, 2 x 108 C. albicans cells were incubated for 2 hours at 37°C under 5 % CO2 with 300 uCi of Na2 51CrO4 (Amersham International Ltd., Amersham, England), washed three times in saline, counted, and resuspended in medium to a density of 5 x 105 cells/ml. Under standard labeling conditions, 5 x 104 C. albicans cells gave 2,000+500 cpm. Various numbers of effector cells in 0.1 ml were mixed in U-shaped 96-well microtiter plates with 5 x 104 radiolabeled C. albicans cells in 0.1 ml. After 4 hours of incubation at 37°C under 5 % CO2, the plates were centrifuged at 800 x g for 10 minutes. The radioactivity in 0.1 ml of the supernatant was measured on a r-scintillation counter. The base-line 51Cr-release was that of C. albicans incubated alone in complete RPMI 1640 medium, and in no case did it exceed 20% of total counts per minute incorporated by target cells.
Experimental results have been expressed as the percent lysis in the experimental group (quadruplicate samples) above the base-line control by the following formula; specific 51Cr-release (%)=cpm (experimental group)-cpm (spontaneous release)/(0.5 x total cpm) x 100, where total cpm is the radioactivity incorporated by 5 x 104 C. albicans cells.
Plate Counts Phagocytic cells (5 x 105 in 0.1 ml per well) were infected with unlabeled C. albicans cells (5 x 104 cells in 0.01 ml per well). After 1 or 4 hours of incubation at 37°C under 5 % CO2, the plates were vigorously shaken, and serial dilutions were made in distilled water from each well. Plates (duplicate samples) were made by spreading each sample on Sabouraud glucose agar. The number of cfu was determined after 18 hours of incubation at 37°C. Control cultures consisted of C. albicans cells incubated without effector cells.
Phagocytic Activity
The ability of adherent spleen cells to phagocytize heat inactivated C. albicans cells was measured by incubating 5 x 108 cells per ml in U-shaped 96-well microtiter plates with 25 x 108 C. albicans cells per ml for various times.
After the adherent 0.1 ml of spleen cells were incubated with 0.1 ml of yeast cells, the wells were washed. After that the cells were removed and stained with May-Grunwald Giemsa. The number of intracellular C. albicans cells was then determined microscopically by counting the yeast cell content of 100 cells. The counts were done in duplicate by two different observers and the results were averaged.
Statistical Analysis Differences in survival times were analyzed by the Mann-Whitney U-test. Differences in the number of cfu or specific radiolabel release in the in vitro microcytotoxicity assay were determined by the Student's "t" test. To confirm our previous observations on the AmB-induced increase in resistance to C. albicans infection and augmentation of cell-mediated immunity by splenic effectors in vitro1), CD2F1 mice were given a single ip injection of AmB 10 mg/kg at various times before the intravenous challenge with 106
C. albicans cells. Groups of mice receiving the drug according to the same schedule were used as donors of spleen cells to be reacted in vitro against radiolabeled C. albicans particles. Table 1 shows the results. It is apparent that AmB treatment considerably enhanced the in vivo resistance of mice to microbial challenge even when the latter was performed 6-8 days after exposure to the drug, at a time when no direct ("chemotherapeutic") effect of AmB could be expected to occur1). THE JOURNAL OF ANTIBIOTICS changes in the candidacidal potential of spleen cells in vitro followed a pattern most similar to that observed in vivo, with peak levels of reactivity at about 6 days after treatment. One thing to be noted in this experiment is that at no time after AmB exposure did spleen cellularity change, thus suggesting that activation was the major cellular mechanism involved in the in vivo effect. a AmB (10 mg/kg) was given as a single ip injection a number of days before microbial challenge or collection of splenocytes for the in vitro assay (day 0). b 8-Week old CD2F1 mice were challenged by iv route with I x 106 C . albicans cells. To characterize the effector cell responsible for cytotoxic activity against C. albicans in our system, we studied the effects of removal of plastic or nylon adherent cells from the splenic population of AmB-treated animals. Concurrently, the impact of treatment with carbonyl-iron +magnet, which removes phagocytic cells, was also studied. ,a AmB was given ip before microbial challenge or collection of splenocytes for the in vitro assay (day 0) . Various antisera directed against specific cell membrane antigens were used to further characterize the cells responsible for anti-Candida cytotoxic activity in our system after exposure to AmB. Table   3 shows that treatment with anti-Thy 1.2 plus complement or anti-Asialo GM1 plus complement, which affect mature T cells and natural killer lymphocytes, respectively, had no major effect on the candidacidal activity of splenic effectors activated by AmB.
Effect of AmB Treatment Schedule
Previous studies have shown that optimal immunostimulatory anti-Candida effects follow treat-ment of mice with a single dose of AmB 10 mg/kg administered 2-8 days before microbial challenge1).
In the present study, we investigated the impact of repeated drug administrations over a prolonged period of time. Studies were also conducted in order to establish the optimal conditions of in vitro exposure of macrophages which would induce candidacidal activity. Following preliminary indications1), plastic adherent spleen cells from intact mice were incubated in vitro for 3 hours with a range of AmB concentrations (0.1 -20 ug/ml). At the end of the incubation time, the cells were extensively washed and used as effectors in a 51Cr-release and a cfu inhibition assay. Table 5 shows the results. It is apparent that strong anti-Candida activity was achieved by exposure of macrophages to AmB 10 ug/ml. Freezethawed AmB-treated spleen cells had no cytotoxic activity against Candida, thus ruling out any direct involvement of AmB which might have remained associated with the effector cells. In subsequent experiments, the effect of incubation with AmB 10 µg/ml for varying lengths of time was studied. Fig.   1 shows that, on exposure of macrophages to the drug for 15, 30, 60, 120 or 240 minutes or 24 hours, optimal anti-Candida effects were induced by a contact of at least 60 minutes. A series of experiments was also devoted to clarifying some kinetic aspects of the AmB-induced macrophage activation. Adherent spleen cells, either from intact or AmB-treated (10 mg/kg, day -8) mice were cultured in vitro for varying lengths of time before being tested in a 51Cr-release and cfu inhibition assays. Effector cells activated in vitro by AmB (10 µg/ml, 3 hours) were also assayed according to the same schedule. Fig. 2 shows that all of the effectors tested gradually lost their cytotoxic potential if cultured in vitro in the absence of AmB over a 6-day period.
Kinetics of Phagocytosis by AmB-activated Macrophages
The phagocytic efficiency of macrophages activated by AmB was monitored at different times Plastic adherent spleen cells from normal CD2F1 mice were incubated in vitro with medium or AmB (10 ug/ml) for various times. After that the effector cells were repeatedly washed and assayed against C. albicans target cells.
Data are the means of quadruplicate samples. Standard errors, usually <1.5% for chromium release assay (CRA) and <4.5 % for cfu assay have been omitted. Ratio of effectors to target cells was 10: 1 for CRA and 2.5: 1 for cfu assay.
Arrows, P<0.01 (AmB-treated versus untreated cells) according to Student's "t" test. AmB (10 mg/kg) was given ip as a single injection 8 days before collection of splenocytes for the in vitro assay. Plastic adherent spleen cells from normal mice were incubated for 2 hours with AmB (10µg/ml).
Plastic adherent spleen cells from normal or AmB-treated mice or activated in vitro with AmB were cultured at different times before their use as effector cells against C. albicans.
CRA (A) and cfu (B) assays were performed at effector to target ratio of 10: 1 and 5: 1 respectively. Standard errors, usually <1.5% for CRA and <4.5% for cfu assay, have been omitted. Arrows, P<0.01 (AmB-treated versus untreated cells) according to Student's "t" test.
VOL. XXXIX NO. 6 THE JOURNAL OF ANTIBIOTICS during the incubation of the effector cells with inactivated C. albicans microorganisms. Fig. 3 shows the results in terms of number of yeast particles ingested by a single phagocytic cell at 1 and 4 hours of incubation. It appears that the phagocytic activity of AmB-treated macrophages was considerably higher than that of controls. In another experiment, adherent spleen cells from intact or AmB-treated (10 mg/kg, day -8) mice were incubated in vitro with inactivated C. albicans at the ratio of 1: 5. Fig. 4 shows the results in terms of number of ingested yeast particles per 100 effectors as well as percentage of cells that had ingested at least one C. albicans particle. Again, the AmB-activated macrophages displayed an enhanced phagocytic ability. 
Discussion
The present paper follows previous observations by our group that AmB can exert considerable anti-Candida activity through a mechanism largely independent of its chemotherapeutic properties1). Indeed, this activity appeared in our preliminary investigations to be rather related to the immunoadjuvant effects that AmB has been shown to exert in experimental tumor 12) as well as infection models13,14). The majority of these studies indicated activated macrophages as the principal mediators of the immunoadjuvant activity of AmB15-17) Our present study shows that cells with candidacidal properties can be recovered from mice treated with AmB. These cells appear to be macrophages by both morphological and functional criteria. They are activated in vivo by AmB in a dose-dependent fashion under selected treatment conditions. A single dose of 10 mg/kg has effects comparable to those of 5 daily exposures to 2 mg/kg. The activity is lost when the repeated dosages are given on an alternate day basis. No additional benefits, on the other hand, are obtained if the cumulative dose is raised to 50 mg/kg. Thus, macrophage activation by AmB seemed to develop over a prolonged period of time following administration of the drug in adequate amounts. In vitro studies of macrophage activation by AmB were performed in which we tested different AmB concentrations and different exposure times. Again there appeared to be a threshold value (10 pg/ml) below which no significant activation could be obtained. Macrophage activation, which was evident in both the chromium release assay (CRA) and cfu inhibition tests, gradually declined when the cells, activated either in vivo or in vitro, were kept under in vitro conditions for varying lengths of time before testing. Studies were also devoted to clarifying the mechanisms by which the activated macrophages exert the increased antiCandida activity.
It was found that the phagocytic efficiency of AmB-activated macrophages was considerably enhanced with respect to untreated controls both in terms of kinetic parameters of phagocytosis as well as total numbers of Candida particles ingested.
Moreover, on incubation of AmBactivated macrophages with live Candida, marked inhibition of hyphae formation was observed (data not shown).
In conclusion, the data of the present paper suggests the concept that in vitro or in vivo exposure of macrophages to AmB results in increased candidacidal activity. This observation might be useful toward a more thorough understanding of the mechanisms underlying the therapeutic efficacy of AmB as an antifungal agent. 
